Ok, so I’ve been a little busy as of late. What have I been doing that was just too much to spend a few minutes writing of how unpredictable IFRX can be? Laying groundwork for a future return of investment. No, not researching stocks or buying other penny stocks, but planting crops on my day! (Father’s Day). Its that time of the year to make sure that a few restless nights and long days in the sun make a return in 5 months (unlike my current stock selections). But what has happened over the past week? 5% return of course. 10Am on 12JUN we were at $3.06, and today we’ve closed at $3.25. Sure we’ve topped at $3.55, but that’s neither here nor there, lets just focus on a positive, ok?
It is important to start looking at factors such as this, because that’s what Chap 2 is about; Competitive Advantage and statistical representation of organizational success or failure. How does one measure a company against another? Because they have a better name? A better advertising agency? Of course not. Numbers are everything in the world of business, and if an executive board cant correctly highlight what they are doing, they wont last long.
In addition to numbers, we must always relate back to the intangibles. What makes a company what it is, what sets it apart, what makes people keep coming back? In the case of IFRX, they were a company that was focusing on a select number of treatments that other organizations were unable to cure. What we have to examine though, is if what IFRX is trying to cure, is curable. They’ve been losing millions in cash as they spend countless assets on R&D, on Clinical Trials, and other such adventures, only their flagship treatments, have yet to set sail and have rather spent more time shipwrecked than the Titanic. Its time that a positive course is found with IFRX, or at least some positive news to turn their stock value around
IFRX 